BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For
more
information on access to our products, please call our
customer service line at 1-800-469-0261.
BDSI helps develop technologies designed to deliver increased bioavailability in the treatment of serious and debilitating chronic conditions.
BioErodible MucoAdhesive (BEMA®) technology uses a small polymer film applied to the inner lining of the cheek for rapid drug administration. Delivering medication across the mucous membranes, this bioerodible film helps optimize time-sensitive treatments. It is also beneficial for facilitating the administration of drugs where poor oral absorption is an issue.
Oral Presentation of Data from Phase I Safety Study & Secondary Respiratory Outcomes Comparing BELBUCA ® to Oxycodone on January 16 from 1:10pm – 2:10pm CT RALEIGH, N.C. , Jan. 15, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty
Read moreRALEIGH, N.C. , Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeff Bailey , Chief Executive Officer, and
Read moreRALEIGH, N.C. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Chief Executive Officer, and
Read moreThere are no events to display
Stay up to date on the latest news
Get started now